CALC Phase 2 readout: a positive outcome, +8.9%

On April 15, 2026, Auxora — CalciMedica, Inc. (Acute Kidney Injury) reached its Phase 2 readout. The result was a positive outcome, and the stock moved +8.9% in the window around the event. It had already run +12.2% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.